by Dr. C.H. Weaver M.D. 12/2018
The BiTE® antibody construct represent an innovative immunotherapy approach that helps the body’s immune system target cancer cells and appears very promising for the treatment of lymphomas and multiple myeloma.
BiTE is short for "bispecific T cell engager". BiTEs are antibodies with two arms. One arm of the drug attaches to a specific protein on the tumor cell. The other arm of the BiTE activates immune cells in the patient to kill the cancer cells.
CAR-T cell therapy was the major innovation highlighted at last year’s Annual American Society of Hematology (ASH) Meeting. This year its BiTE, and a big question is whether BiTE could ultimately be more broadly beneficial that CAR-T?
There are several differences but a key one is that BiTEs has the advantage of being “off the shelf” meaning the same product can be given to all patients. CAR-Ts must be made from cells taken from each patient and hence is more time consuming and potentially more expensive.
Blincyto was the first BiTE® antibody constructs developed and was approved for the treatment of Acute Lymphoblastic Leukemia in 2015. The BiTE® antibody construct is designed to direct the body’s cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blincyto as been demonstrated to prolong survival in acute lymphoblastic leukemia and doctors are working to determine the best may to incorporate it into the overall treatment strategy. Learn more about Blincyto in ALL.
In a Phase 1 proof-of-concept trial, the experimentaly REGN1979 bispecific antibody demonstrated a 100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma. REGN1979 is a bispecific monoclonal antibody designed to trigger the killing of cancer cells by binding to both CD3 on immune system T-cells and CD20 on B-cell lymphomas. ASH study results for REGN1979
AMG420 is a BiTE antibody construct drug that acts as a bridge between the BCMA portion of an antigen on the surface of a myeloma cell, and the CD3 binds to the surface of a T-cell. This bridge forms the way in which Cytotoxic T-Lymphocytes (CTLs) attack and kill the myeloma cells.
Results from the study evaluating AMG 420 in patients with relapsed/refractory multiple myeloma who had received at least two prior lines of treatment showed a 31% response rate, including seven complete responses. The response rate in patients receiving the highest dose evaluated was 70% with 86% of the responders maintaining their responses for up to 7.5 months.
Side effects at the highest doses were peripheral polyneuropathy which improved to baseline after IV immunoglobulin and corticosteroid treatment and cytokine release syndrome.
More About BiTE® Technology
Bispecific T cell engager (BiTE®) antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the body’s immune system to detect and target malignant cells. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. BiTE® antibody constructs help place the T cells within reach of the targeted cell, with the intent of allowing T cells to inject toxins and trigger the cancer cell to die (apoptosis). BiTE® antibody constructs are currently being investigated for their potential to treat a wide variety of cancers. For more information, visit www.biteantibodies.com.